Search results: (10000)
News Treatment of Glaucoma: Without Preservatives for Everyone?
A comprehensive report by Professor John Thygesen from the University Hospital in Copenhagen analyzes patient groups for whom preservative-free antiglaucoma medications are particularly suitable. In conclusion, he suggests that if there are no price differences, widespread treatment with preservative-free preparations is preferable.
News ESC 2022: Heart Failure with Preserved Ejection Fraction as an Underdiagnosed Problem: How to Increase Its Detection in Everyday Practice?
During this year's European Society of Cardiology Congress (ESC 2022), alarming information was shared, indicating that heart failure with preserved ejection fraction of the left ventricle (HFpEF) is likely underdiagnosed in clinical practice, necessitating improved identification and detection of patients with this condition. One of the symposiums addressed not only the reasons why many patients with HFpEF are misdiagnosed.
News Micronized Diosmin Obtained Reimbursement, Based on Its Therapeutic Interchangeability with MPFF
On January 11, 2022, the State Institute for Drug Control (SÚKL) issued a decision on the determination of the amount and conditions of reimbursement from health insurance for a drug containing micronized diosmin. The reimbursement is valid from March 1, 2022.
News The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease
Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney disease, heart failure, or high cardiovascular (CV) risk. A recent study published in the Clinical Journal of the American Society of Nephrology (CJASN) assessed whether long-term use of SGLT2i brings benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4i, i.e., gliptins) in diabetics without documented CV or renal disease using data from a large Israeli database.
News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study
Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
News Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results
A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer products with an extended elimination half-life.
News Prof. Petra Lišková: Prevention of Dry Eye Syndrome is Difficult but Not Impossible
Dry eye syndrome is one of the most common ophthalmological problems, and its incidence is rising. Ophthalmologist Prof. MUDr. Petra Lišková, Ph.D., from the Clinic of Pediatrics and Hereditary Metabolic Disorders of the First Faculty of Medicine, Charles University, and University Hospital in Prague, explains how these difficulties arise and why patients should visit an eye doctor rather than relying solely on self-treatment.
News Combination of Candesartan with ACE Inhibitors in the Treatment of Hypertension and Heart Failure
Although the combination of ACE inhibitors and sartans is not recommended due to the higher incidence of complications, studies also indicate a positive effect of their concurrent administration. The potential use of dual blockade of the renin-angiotensin-aldosterone system (RAAS) is suggested in resistant hypertension, and results have also been described in the treatment of congestive heart failure. What do the recommendations say?
News How Important is the Time Factor in the Treatment of Heart Failure?
Current guidelines emphasize the importance of early diagnosis and immediate treatment for patients with heart failure (HF). These patients are most vulnerable immediately after the decompensation of chronic HF, and intensive treatment can therefore reduce the risk of further hospitalization and mortality. The prognosis for these patients is unfavorable, and any delay in initiating therapy further worsens it. The treatment of chronic HF is often postponed if the symptoms are stable, and the risk of adverse outcomes and sudden death is underestimated. The time factor thus plays a significant role in all stages of HF.
News Epstein-Barr Virus – Is the Culprit of MS Revealed?
Could the Epstein-Barr virus hold the answer to the etiology of multiple sclerosis? A dataset of over 10 million American recruits offered intriguing insights. You may have encountered the conclusions of one of the most extensive studies in modern history in the media. Let's take a closer look at the work of Kjetil Bjornevik and his colleagues.
News Current Insights into the Etiology of Community Pneumonia: Pneumococci Still Leading?
The etiology of community-acquired pneumonias has undergone certain changes since the beginning of the antibiotic era. According to current guidelines, it is still recommended to initiate empirical antibiotic therapy upon diagnosing community-acquired pneumonia. However, there are certain concerns associated with the recommendation of empirical antibiotic therapy, especially regarding the increasing occurrence of bacterial antibiotic resistance. The aim of the study presented below was to specify the most frequently isolated pathogens of community-acquired pneumonia between 1945 and 2020.
News Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling
A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters (not only) in patients with HFrEF. The authors focused on both the presence and significance of changes, as well as the speed of their onset after the initiation of treatment.
News Full Compensation of Seizures as the Main Goal of Epilepsy Therapy: Will Patients Achieve It More Easily Than 20 Years Ago?
What is the relationship between the quality of life of patients and the degree of seizure compensation? Have the new antiepileptics (ASM) developed over the last decades improved the overall success rate of therapy?
News Long-term Efficacy of Targeted Therapy for Axial Spondyloarthritis
How does etanercept fare in the long-term treatment of early axial spondyloarthritis (axSpA)? Data from over 10 years of follow-up in patients with both radiographic and non-radiographic forms of axSpA were recently published in the journal Therapeutic Advances in Musculoskeletal Disease as part of the extended clinical trial ESTHER.
News Factors Influencing the Occurrence of Prosthetic Stomatitis in Patients with Complete Denture
Dental dentures are removable replacements made for partial or complete loss of teeth. Quality denture treatment is a long-lasting process in which oral hygiene and denture hygiene play a key role.
News Ocrelizumab in the Treatment of Multiple Sclerosis – 10-Year Data
Multiple sclerosis (MS) is a lifelong disease with a high risk of permanent disability. Current information on the long-term efficacy and safety of treatment is therefore absolutely essential for the optimal choice of therapeutic agent – in this case, ocrelizumab.
News Treatment of Schizophrenia in Light of New Findings
"Mental disorders constitute a significant burden on society," began Assoc. Prof. MUDr. Martin Anders, Ph.D., head of the Psychiatric Clinic at the First Faculty of Medicine, Charles University and General University Hospital in Prague, during his presentation at the psychiatric symposium titled "A Chance for a Better Life with Schizophrenia Diagnosis," held on October 18, 2021, in Prague. His lecture focused on key issues in the treatment of schizophrenia, as well as on one of the recently registered antipsychotics—lurasidone.
News Identification of patients with advanced Parkinson's disease suitable for device-aided therapy (DAT)
To properly implement device-aided therapy in Parkinson's disease (PD) management, it is essential to timely identify patients in advanced stages of the disease who might benefit from this therapeutic approach. We summarize the useful tools that doctors can use to find these patients.
News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases
Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.
News Balance and Rehabilitation – Firm on the Ground Even with Multiple Sclerosis
A large portion of patients with multiple sclerosis (MS) suffer from balance disorders. What are the options for non-pharmacological therapy for these issues according to the latest studies?